Nationwide Fund Advisors increased its stake in shares of Emergent Biosolutions Inc. (NYSE:EBS) by 17.4% during the third quarter, Holdings Channel reports. The institutional investor owned 51,243 shares of the biopharmaceutical company’s stock after buying an additional 7,600 shares during the period. Nationwide Fund Advisors owned approximately 0.13% of Emergent Biosolutions worth $1,616,000 at the end of the most recent reporting period.
Other institutional investors also recently made changes to their positions in the company. PineBridge Investments L.P. boosted its position in shares of Emergent Biosolutions by 5.4% in the second quarter. PineBridge Investments L.P. now owns 3,964 shares of the biopharmaceutical company’s stock valued at $112,000 after buying an additional 202 shares in the last quarter. Teacher Retirement System of Texas raised its stake in Emergent Biosolutions by 22.5% in the second quarter. Teacher Retirement System of Texas now owns 4,707 shares of the biopharmaceutical company’s stock valued at $132,000 after buying an additional 866 shares during the last quarter. Howe & Rusling Inc. raised its stake in Emergent Biosolutions by 3.0% in the second quarter. Howe & Rusling Inc. now owns 4,875 shares of the biopharmaceutical company’s stock valued at $137,000 after buying an additional 140 shares during the last quarter. Mason Street Advisors LLC acquired a new stake in Emergent Biosolutions during the second quarter valued at approximately $172,000. Finally, Springbok Capital Management LLC acquired a new stake in Emergent Biosolutions during the first quarter valued at approximately $192,000. Institutional investors own 88.89% of the company’s stock.
Shares of Emergent Biosolutions Inc. (NYSE:EBS) traded up 2.03% on Friday, hitting $30.14. 233,768 shares of the stock traded hands. The stock has a market cap of $1.22 billion, a P/E ratio of 28.54 and a beta of 1.03. The stock’s 50 day moving average price is $28.81 and its 200 day moving average price is $31.80. Emergent Biosolutions Inc. has a 52-week low of $24.47 and a 52-week high of $44.38.
Emergent Biosolutions (NYSE:EBS) last released its earnings results on Monday, November 7th. The biopharmaceutical company reported $0.58 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.26 by $0.32. The firm earned $142.91 million during the quarter, compared to analyst estimates of $112.30 million. Emergent Biosolutions had a net margin of 9.12% and a return on equity of 10.42%. The business’s revenue was down 9.8% on a year-over-year basis. During the same quarter last year, the business earned $0.93 EPS. On average, equities analysts expect that Emergent Biosolutions Inc. will post $1.02 EPS for the current fiscal year.
Several research firms recently commented on EBS. Wells Fargo & Co. set a $41.00 price objective on shares of Emergent Biosolutions and gave the stock a “buy” rating in a research note on Saturday, October 1st. Cowen and Company reissued a “hold” rating and set a $33.00 price objective on shares of Emergent Biosolutions in a research note on Sunday, August 7th. Chardan Capital reissued a “buy” rating and set a $47.00 price objective on shares of Emergent Biosolutions in a research note on Wednesday, November 9th. Zacks Investment Research raised shares of Emergent Biosolutions from a “strong sell” rating to a “hold” rating in a research note on Tuesday, October 25th. Finally, JPMorgan Chase & Co. dropped their price objective on shares of Emergent Biosolutions from $45.00 to $36.00 and set an “overweight” rating on the stock in a research note on Friday, August 5th. Two investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. Emergent Biosolutions has a consensus rating of “Buy” and a consensus price target of $40.17.
Emergent Biosolutions Company Profile
Emergent BioSolutions Inc is a biopharmaceutical company that offers specialized products to healthcare providers and governments to address medical needs and emerging health threats. The Company develops, manufactures and delivers a portfolio of medical countermeasures primarily for government agencies in the areas of biological and chemical threats and emerging infectious diseases (EID).